What are Cancer Stem Cells (CSCs) & Tumor Microenvironment (TME)
CSCs are a small subset of tumor cells with abilities of self-renewal, differentiation, often therapy resistance, metastasis, and relapse.
The TME includes everything around tumor cells: stromal cells (like fibroblasts, mesenchymal stem/stromal cells), immune cells, the extracellular matrix (ECM), blood vessels, signaling molecules (cytokines, chemokines), exosomes, hypoxia zones, etc. CSCs both influence and are influenced by this environment.
Recent Emerging Biomarkers of CSCs & their Interplay with the TME
These are molecular features or markers that help identify CSCs, predict behavior (metastasis, relapse), or might serve as therapeutic targets.
| Biomarker / Feature | Role (diagnostic / prognostic / therapeutic) | TME-related Interaction |
| CD24, CD44, CD133 etc. | Classic surface markers used to identify CSCs in many solid tumors. For example, CD133 in liver cancer; CD24 in several cancers. (Frontiers) | These markers often correlate with enhanced ability to survive under hypoxia, resist therapy, interact with stromal cells. (Frontiers) |
| Transcription factors: OCT4, NANOG, SOX2, c-MYC | These maintain “stemness” (i.e. the ability to self-renew, resist differentiation). High expression is associated with therapy resistance. (Frontiers) | Their expression is modulated by TME signals: e.g. hypoxia upregulates HIFs, which raise OCT4, etc. (Frontiers) |
| Drug transporters / ABC transporters | Markers that mediate resistance (pumping out therapeutic agents) — clinically useful for predicting which tumors might be resistant. (Frontiers) | The TME may support expression of these transporters via signaling from stromal cells or via exosomal communication. (BioMed Central) |
| Exosomal RNAs (non-coding) | Emerging biomarker: exosomes carry non-coding RNAs (miRNAs, lncRNAs) that reflect CSC status; some may regulate CSC behaviour in distant or neighboring cells. (Science) | The TME uses exosomes for communication: exosomes from CSCs can modulate stromal or immune cells; conversely, stromal/immune cells send exosomes that affect CSCs. (BioMed Central) |
| Immune checkpoint molecules & immune evasion markers | E.g. PD-L1 expression, regulatory T cell (Treg) involvement, suppression of effector immune cells. These help CSCs evade immune attack and may predict response to immunotherapy. (Frontiers) | TME immune composition is crucial; the presence of immunosuppressive macrophages (M2), Tregs, etc., is often linked to worse outcomes and higher CSC activity. (BioMed Central) |
Mechanisms of Crosstalk: How TME Supports CSCs
Some recent insights on how the microenvironment helps CSCs survive, proliferate, evade therapies, and contribute to metastasis:
- Hypoxia (low-oxygen zones): triggers HIF (hypoxia-inducible factors), leading to upregulation of stemness genes (OCT4, NANOG, c-MYC). Hypoxia also tends to make CSCs more drug resistant and more capable of invasion.
-
Exosome / extracellular vesicle communication: Exosomes from stromal or immune cells deliver signals (RNAs, proteins) to CSCs that influence their phenotype. Also, CSCs send exosomes influencing TME.
- Inflammatory signals / immune cell interactions: Cytokines like IL-6, IL-8, others are secreted by TME cells (e.g., cancer-associated fibroblasts, mesenchymal stem/stromal cells) and strengthen CSC traits (EMT, migration, survival). Meanwhile, CSCs can shape immune suppression.
- Metabolic reprogramming & microenvironment acidity: Low pH, accumulation of metabolites (like lactate), changes in nutrient availability can favor CSCs, help them survive stress, resist therapies.
Therapeutic Frontiers & Recent Trials / Promising Strategies
These are some of the new or evolving methods to try to target CSCs and/or disrupt the TME to reduce CSC-driven relapse, resistance, metastasis.
CSC-directed clinical trials / therapies
There is growing interest in therapies that target known CSC biomarkers or pathways (e.g. anti-Notch, Hedgehog, WNT/β-catenin inhibitors). Some agents are in early clinical trials.
Combining CSC-targeting agents with standard therapies, to reduce relapse by hitting both bulk tumor cells and CSCs.
Targeting hypoxia / HIF pathway
Because hypoxia is central to CSC maintenance, inhibitors of HIF or its downstream pathways are being explored.
Also, therapies aiming to reoxygenate tumors or disrupt hypoxic niches.
Exosome / extracellular vesicle inhibitors or modulators
Blocking or altering exosome release or uptake to prevent pathological signaling
Modulating immune microenvironment / immune checkpoint therapies
Enhancing immune response against CSCs via checkpoint inhibitors, or by reducing immunosuppressive cellular components (like M2 macrophages, Tregs).
Possibly using markers to stratify patients: if a tumor shows markers of high CSC + immunosuppressive TME, it may benefit more from a specific immunotherapy combo.
Ferroptosis & novel death pathways
Some small molecules and repurposed compounds (e.g. artemisinin derivatives) are being considered to force CSCs into ferroptosis (an iron-dependent cell death).
Nanoparticle approaches, or engineered delivery systems, are also under study to target CSCs more specifically.
3D culture models / Organoids / Single-cell sequencing to better capture the CSC-TME interaction
These models allow researchers to observe how CSCs behave in more realistic TME settings (with stromal, immune cell components). They help identify new biomarkers / therapeutic vulnerabilities.
Single-cell RNA sequencing has revealed heterogeneity among CSCs and identified subpopulations with different susceptibilities or behaviors under therapy
